Glaxo And Novartis Scratch Each Other’s Back With Consumer Product JV

The combination of the firm’s consumer portfolios will create the No. 1 global OTC business, Duetsche Bank analysts say. GSK estimates OTC sales from JV will reach $5.72 billion, representing more than half of the $10 billion in overall annual sales anticipated for the consumer health product JV.